6 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: ... Full Year and Q4 2024 results clinical trials appendix. PDF 2,467KB Explore our clinical trials appendix. Adrian Kemp Company Secretary AstraZeneca PLC . tags. Corporate and financial

6 days ago · On Thursday 6 February 2025 we announced our Full Year and Q4 2024 results. An accompanying webcast for investors and analysts took place at 11:00 UK time.

6 days ago · Accelerating AstraZeneca’s strategic and financial development: AstraZeneca to acquire Alexion

5 days ago · Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m, driven by a 19% increase in Product Sales, continued growth of partnered...

5 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also ...

Feb 5, 2025 · Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also...

6 days ago · AstraZeneca continues to fully cooperate with the Chinese authorities. In December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International, which encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.

5 days ago · Total Revenue Growth: Up 21% for the full year 2024. Core EPS Growth: Increased by 19% in 2024. Core Operating Expense Growth: Increased by 14% in 2024. China Revenue Growth: Increased by 11% for ...

6 days ago · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively.

6 days ago · Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025